198 related articles for article (PubMed ID: 35204461)
21. Viewing the Eph receptors with a focus on breast cancer heterogeneity.
Nikas I; Ryu HS; Theocharis S
Cancer Lett; 2018 Oct; 434():160-171. PubMed ID: 30055288
[TBL] [Abstract][Full Text] [Related]
22. Association of CD44 and CD24 phenotype with lymph node metastasis and survival in triple-negative breast cancer.
Zou W; Yang Y; Zheng R; Wang Z; Zeng H; Chen Z; Yang F; Wang J
Int J Clin Exp Pathol; 2020; 13(5):1008-1016. PubMed ID: 32509072
[TBL] [Abstract][Full Text] [Related]
23. [Clinical features and prognosis of patients with first-episode liver metastasis of different molecular subtypes of breast cancer].
Wu SY; Tan Y; Guan YS
Zhonghua Gan Zang Bing Za Zhi; 2016 Jun; 24(6):422-8. PubMed ID: 27465945
[TBL] [Abstract][Full Text] [Related]
24. EPH/ephrin profile and EPHB2 expression predicts patient survival in breast cancer.
Husa AM; Magić Ž; Larsson M; Fornander T; Pérez-Tenorio G
Oncotarget; 2016 Apr; 7(16):21362-80. PubMed ID: 26870995
[TBL] [Abstract][Full Text] [Related]
25. Global evaluation of Eph receptors and ephrins in lung adenocarcinomas identifies EphA4 as an inhibitor of cell migration and invasion.
Saintigny P; Peng S; Zhang L; Sen B; Wistuba II; Lippman SM; Girard L; Minna JD; Heymach JV; Johnson FM
Mol Cancer Ther; 2012 Sep; 11(9):2021-32. PubMed ID: 22807579
[TBL] [Abstract][Full Text] [Related]
26. Targeting EphA2 impairs cell cycle progression and growth of basal-like/triple-negative breast cancers.
Song W; Hwang Y; Youngblood VM; Cook RS; Balko JM; Chen J; Brantley-Sieders DM
Oncogene; 2017 Oct; 36(40):5620-5630. PubMed ID: 28581527
[TBL] [Abstract][Full Text] [Related]
27. miR-200a inhibits migration of triple-negative breast cancer cells through direct repression of the EPHA2 oncogene.
Tsouko E; Wang J; Frigo DE; Aydoğdu E; Williams C
Carcinogenesis; 2015 Sep; 36(9):1051-60. PubMed ID: 26088362
[TBL] [Abstract][Full Text] [Related]
28. Prognostic significance of proline, glutamic acid, leucine rich protein 1 (PELP1) in triple-negative breast cancer: a retrospective study on 129 cases.
Zhang Y; Dai J; McNamara KM; Bai B; Shi M; Chan MS; Liu M; Sasano H; Wang X; Li X; Liu L; Ma Y; Cao S; Xing Y; Zhao B; Song Y; Wang L
BMC Cancer; 2015 Oct; 15():699. PubMed ID: 26472563
[TBL] [Abstract][Full Text] [Related]
29. MiR-34b is associated with clinical outcome in triple-negative breast cancer patients.
Svoboda M; Sana J; Redova M; Navratil J; Palacova M; Fabian P; Slaby O; Vyzula R
Diagn Pathol; 2012 Mar; 7():31. PubMed ID: 22439831
[TBL] [Abstract][Full Text] [Related]
30. Downregulation of antigen presentation-associated pathway proteins is linked to poor outcome in triple-negative breast cancer patient tumors.
Pedersen MH; Hood BL; Beck HC; Conrads TP; Ditzel HJ; Leth-Larsen R
Oncoimmunology; 2017; 6(5):e1305531. PubMed ID: 28638726
[TBL] [Abstract][Full Text] [Related]
31. EPHA2 antisense RNA modulates EPHA2 mRNA levels in basal-like/triple-negative breast cancer cells.
Okuyama T; Sakamoto R; Kumagai K; Nishizawa M; Kimura T; Sugie T; Kimura T
Biochimie; 2020 Dec; 179():169-180. PubMed ID: 33022313
[TBL] [Abstract][Full Text] [Related]
32. High expression of LC3B is associated with progression and poor outcome in triple-negative breast cancer.
Zhao H; Yang M; Zhao J; Wang J; Zhang Y; Zhang Q
Med Oncol; 2013 Mar; 30(1):475. PubMed ID: 23371253
[TBL] [Abstract][Full Text] [Related]
33. TMPRSS4 as a poor prognostic factor for triple-negative breast cancer.
Cheng D; Kong H; Li Y
Int J Mol Sci; 2013 Jul; 14(7):14659-68. PubMed ID: 23857060
[TBL] [Abstract][Full Text] [Related]
34. Overexpression of the receptor tyrosine kinase EphA4 in human gastric cancers.
Oki M; Yamamoto H; Taniguchi H; Adachi Y; Imai K; Shinomura Y
World J Gastroenterol; 2008 Oct; 14(37):5650-6. PubMed ID: 18837080
[TBL] [Abstract][Full Text] [Related]
35. Prognostic impact of EGFR and cytokeratin 5/6 immunohistochemical expression in triple-negative breast cancer.
Abdelrahman AE; Rashed HE; Abdelgawad M; Abdelhamid MI
Ann Diagn Pathol; 2017 Jun; 28():43-53. PubMed ID: 28648939
[TBL] [Abstract][Full Text] [Related]
36. The Value of EphB2 Receptor and Cognate Ephrin Ligands in Prognostic and Predictive Assessments of Human Breast Cancer.
Ebrahim AS; Hailat Z; Bandyopadhyay S; Neill D; Kandouz M
Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360867
[TBL] [Abstract][Full Text] [Related]
37. Ephrin B3 interacts with multiple EphA receptors and drives migration and invasion in non-small cell lung cancer.
Efazat G; Novak M; Kaminskyy VO; De Petris L; Kanter L; Juntti T; Bergman P; Zhivotovsky B; Lewensohn R; Hååg P; Viktorsson K
Oncotarget; 2016 Sep; 7(37):60332-60347. PubMed ID: 27533087
[TBL] [Abstract][Full Text] [Related]
38. Clinicopathological characteristics of triple negative breast cancer at a tertiary care hospital in India.
Dogra A; Doval DC; Sardana M; Chedi SK; Mehta A
Asian Pac J Cancer Prev; 2014; 15(24):10577-83. PubMed ID: 25605142
[TBL] [Abstract][Full Text] [Related]
39. Gene expression in triple-negative breast cancer in relation to survival.
Wang S; Beeghly-Fadiel A; Cai Q; Cai H; Guo X; Shi L; Wu J; Ye F; Qiu Q; Zheng Y; Zheng W; Bao PP; Shu XO
Breast Cancer Res Treat; 2018 Aug; 171(1):199-207. PubMed ID: 29748761
[TBL] [Abstract][Full Text] [Related]
40. S100A14 is a novel independent prognostic biomarker in the triple-negative breast cancer subtype.
Ehmsen S; Hansen LT; Bak M; Brasch-Andersen C; Ditzel HJ; Leth-Larsen R
Int J Cancer; 2015 Nov; 137(9):2093-103. PubMed ID: 25912829
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
